Aberrant DNA methylation in ovarian cancer is there an epigenetic predisposition to drug response?

被引：32

作者：

Wei, SH

Brown, R

Huang, THM

机构：

[1] Univ Missouri, Ellis Fischel Canc Ctr, Dept Pathol & Anat Sci, Columbia, MO 65203 USA

[2] Univ Glasgow, Beatson Labs, Canc Res UK, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland

来源：

EPIGENETICS IN CANCER PREVENTION: EARLY DETECTION AND RISK ASSESSMENT | 2003年 / 983卷

关键词：

DNA methylation; microarray; high-throughput; drug-resistance; chemotherapy; cisplatin; and mismatch repair;

D O I：

10.1111/j.1749-6632.2003.tb05979.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.

引用

页码：243 / 250

页数：8

共 27 条

[1] DNA methylation and ovarian cancer [J].